Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Peanut flour OIT Clear all
Completed Phase 1 Interventional Results available

Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)

NCT02203799
View directory record Official record
Conditions
Peanut Allergic Subjects
Interventions
Peanut Oral Immunotherapy (POIT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 16 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy, Omalizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Oral Immunotherapy (OIT) for Peanut Allergy

NCT00815035
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut OIT, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

NCT01274429
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

NCT00932828
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
9 Months to 36 Months
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Peanut Allergy (PMIT)

NCT00597675
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut OIT, Placebo
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Oral Peanut Immunotherapy

NCT01324401
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour OIT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children

NCT01867671
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 48 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Mechanisms of Desensitization During Peanut Oral Immunotherapy

NCT01814241
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Open label peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

NCT03345160
View directory record Official record
Conditions
Treatment Efficacy
Interventions
Peanut Flour
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
4 Years to 9 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 6:24 AM EDT
Active, not recruiting No phase listed Observational

Food Oral Immunotherapy for Peanut Allergy

NCT04222491
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Months to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 25, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Salvage Peanut Oral Immunotherapy Study

NCT03251508
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 25, 2026, 6:24 AM EDT